SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today ...

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...

Inc.) "This study provides the first clinical proof-of-concept that DNA-encoded monoclonal antibodies can be durably and tolerably expressed in humans," said David B. Weiner, Ph.D, Executive Vice ...

(RTTNews) - INOVIO (INO) announced promising interim results from an ongoing Phase 1 proof-of-concept ... trial is being led by The Wistar Institute in collaboration with INOVIO, AstraZeneca, and ...

SolasCure, a Cambridge biotech developing a novel treatment to transform chronic wound healing, has initiated a new Phase II ...

Inovio (INO) announced promising interim results from an ongoing Phase 1 proof-of-concept trial evaluating DMAbs for COVID-19. In the trial, ...

Inc.) "This study provides the first clinical proof-of-concept that DNA-encoded monoclonal antibodies can be durably and tolerably expressed in humans," said David B. Weiner, Ph.D, Executive Vice ...

Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025Commercial launch in the PRC of generic nintedanib for the ...

Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion dis ...

High levels of ammonia kill liver cells by damaging the mitochondria that power the cells. But this can be prevented using an existing drug due to start clinical trials, finds a new study in mice.

EnnoDC presents positive Phase I data at CROI 2025, demonstrating long-lasting immunity induced by Antibody Mediated Vaccines (AMVs) ...